Meeting
2017 ASCO Annual Meeting
Immunological targeting of CD133 in recurrent glioblastoma: A multi-center phase I translational and clinical study of autologous CD133 dendritic cell immunotherapy.
Authors
Jeremy David Rudnick
Cedars-Sinai Medical Center, Los Angeles, CA
Jeremy David Rudnick , Karen L. Fink , Joseph C. Landolfi , James Markert , David Eric Piccioni , Michael J. Glantz , Steven J. Swanson , Anthony Gringeri , John Yu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02049489
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2059)
DOI
10.1200/JCO.2017.35.15_suppl.2059
Abstract #
2059
Poster Bd #
301
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
EO2401 (E) peptide immunotherapy + nivolumab (N) +/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE.
First Author: Wolfgang Wick
Poster
2022 ASCO Annual Meeting
Evaluation of tumor responses and overall survival in patients with recurrent glioblastoma (GBM) from a phase IIa trial of a CMV vaccine immunotherapeutic candidate (VBI-1901).
First Author: Patrick Y. Wen
Poster
2018 Gastrointestinal Cancers Symposium
Clinical significance of high expression of a specific solute carrier transporter in HCC.
First Author: Patricia Gifu
Poster
2012 ASCO Annual Meeting
Correlation of survival with tumor antigen expression in patients with newly diagnosed glioblastoma receiving a multi-epitope pulsed dendritic cell vaccine.
First Author: Surasak Phuphanich